10-K: PMGC Holdings Shifts Focus to Biotech, Reports Full Year 2024 Results

Sentiment:

Annual Report 28 March 2025 1:30 AM

PMGC Holdings Inc. divests its skincare business to concentrate on biotechnology assets, reporting a net loss of $6.25 million for fiscal year 2024.

Capital raiseThe company will need additional capital to conduct its operations and develop its products, and its ability to obtain the necessary funding is uncertain.Additional financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available on acceptable terms, or at all.Additional equity financing could result in significant dilution to our stockholders, and any debt financings will likely involve covenants restricting our business activities.

Worse than expectedThe company reported a net loss of $6,245,737 for the year ended December 31, 2024, compared to a net loss of $4,301,517 in 2023, indicating a worsening financial performance.The company's financial statements have been prepared on a going-concern basis, and its continued operations are in doubt, raising concerns about its ability to continue as a viable entity.

Summary

PMGC Holdings Inc. is now focusing on biotechnology after divesting its skincare business in January 2025.
The company manages three wholly-owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC.
Northstrive Biosciences is developing EL-22, a probiotic to preserve muscle mass during weight loss, and plans to file an IND with the FDA in 2025.
PMGC Research Inc. focuses on R&D in Canada, leveraging government grants.
PMGC Capital LLC is a multi-strategy investment firm.
The company reported a net loss of $6,245,737 for the year ended December 31, 2024, compared to a net loss of $4,301,517 in 2023.
Revenue increased to $2,467,298 for 2024, up from $1,712,595 in 2023.
As of December 31, 2024, the company had net working capital of $4,251,867.
The company intends to grow revenue through PMGC Capital LLC, establish new biotechnology subsidiaries, and pursue acquisitions.
The company faces risks related to financial condition, business operations, and the biotechnology industry.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's strategic pivoting and revenue growth, significant net losses and going concern uncertainties weigh heavily, resulting in a cautious sentiment.

Positives

Strategic shift towards biotechnology, a high-growth sector.
Development of EL-22, a novel approach to address muscle wasting during weight loss.
Revenue growth from $1,712,595 in 2023 to $2,467,298 in 2024.
Net working capital of $4,251,867 as of December 31, 2024.
Focus on strategic acquisitions and capital deployment to drive long-term growth.

Negatives

Net loss of $6,245,737 for the year ended December 31, 2024.
Reliance on external partnerships and licensing agreements for commercialization.
Uncertainty regarding the success of clinical trials and regulatory approvals.
Limited operating history at the current scale.
Dependence on key personnel and consultants.

Risks

The company's financial statements have been prepared on a going-concern basis, and its continued operations are in doubt.
The company has a history of net losses and may not be able to achieve or maintain profitability in the future.
The company will need additional capital to conduct its operations and develop its products, and its ability to obtain the necessary funding is uncertain.
The company's acquired technologies and products under development could be rendered obsolete by technological, regulatory, or medical advances.
The company may be unable to accurately forecast revenue and appropriately plan its expenses in the future.
The outcome of clinical and product testing for the company's portfolio companies is uncertain.
Economic downturns, shifts in healthcare investment trends, regulatory changes, and evolving market demand for biotechnology products could negatively affect the company's business.

Future Outlook

The company intends to focus on growing revenue through PMGC Capital LLC, establishing new biotechnology subsidiaries, utilizing clinical validation studies, advancing clinical development of NorthStrive Biosciences, pursuing additional acquisitions, and evaluating potential spin-offs.

Industry Context

The company is transitioning to a biotechnology holding company focused on acquiring, licensing, and developing biotechnology assets across various pharmaceutical indications. The global biotechnology market is growing, driven by advancements in gene therapies, regenerative medicine, and biologics. The weight-loss drug market has also emerged as a high-growth sector, with GLP-1 receptor agonists driving unprecedented demand.

Comparison to Industry Standards

The document mentions key companies developing GLP-1 drugs and complementary treatments for obesity, including Novo Nordisk, Eli Lilly, Pfizer, Biohaven, Scholar Rock, and Veru.
Novo Nordisk is known for its GLP-1 drugs, Ozempic and Wegovy, which have shown significant efficacy in weight loss and improving cardiovascular health.
Eli Lilly's GLP-1 drug, Mounjaro (tirzepatide), has shown promising results in weight loss, and the company acquired Versanis Bio, which is developing bimagrumab, a drug that helps increase lean muscle mass while reducing fat.
Pfizer is developing danuglipron, an oral GLP-1 analog, aimed at carving out a niche in the obesity market with a more convenient dosing regimen.
Biohaven's taldefgrobep is an investigational fusion protein targeting myostatin to impact skeletal muscle growth relevant to individuals living with overweight and obesity.
Scholar Rock's apitegromab is an inhibitor of the activation of latent myostatin, with the aim of improving patients' motor function and preserving lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity.
Veru's enobosarm is an androgen receptor modulator to address the loss of muscle in patients undergoing weight loss therapy with GLP-1 drugs.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Jordan R. Plews	Graydon Bensler	June 21, 2024	Resignation
Chief Marketing Officer	Brenda Buechler		June 20, 2024	Involuntary termination without cause or laid off from employment as part of a wider job elimination/restructuring or reduction in force of the Company in order to streamline the Company's operations and organizational structure.
Chief Commercial Officer	Christoph Kraneiss		June 20, 2024	Involuntary termination without cause or laid off from employment as part of a wider job elimination/restructuring or reduction in force of the Company in order to streamline the Company's operations and organizational structure.
Director	Jordan R. Plews		December 23, 2024	Resignation

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Adoption of Executive Compensation Recovery Policy	The Company adopted an executive compensation recovery policy or Clawback Policy in compliance with Nasdaq rules. Under our Clawback Policy, if we are required to prepare an accounting restatement due to material noncompliance with the financial reporting requirements under any United States securities laws, we will be entitled to recover (and will seek to recover), from our executive officers, any excess incentive-based compensation received by our executive officers during the three-year period prior to the date on which we are required to prepare the restatement.	2023	This policy applies to both equity-based and cash compensation awards. The excess compensation is the difference between the actual amount that was paid and the amount that would have been paid if the financial statements were prepared properly in the first instance.

Legal Proceedings

As of the date of this Annual Report, there are no active legal proceedings pending or threatened against the Company.

Related Party Transactions

The Company paid consulting fees of $391,333, $110,000, and $95,078 to GB Capital Ltd., a company controlled by Graydon Bensler, Chief Financial Officer and Director in 2024, 2023, and 2022, respectively.
BWL Investments Ltd., a British Columbia Canadian Corporation (BWL) also owned and managed by Braeden Lichti, owned approximately 29.4% of our issued and outstanding shares of Common Stock and 100% of the equity interests in Reactive Labs.
On June 4, 2021, we issued 100 shares of Common Stock (pre 200:1 stock consolidation) to BWL in in exchange for substantially all of the assets and liabilities of Reactive Labs.
As of May 31, 2023, the Company had $192,705 (2022 $120,000, 2021 $23,520) due to NorthStrive, of which $22,705 (2021 $23,520) is unsecured, non-interest bearing and are due on demand.
For the fiscal year ended December 31, 2023, we paid Northstrive $230,000 under the Lichti Consulting Agreement.
For the fiscal year ended December 31, 2024, we paid Northstrive $188,500 under the Second Amended Lichti Consulting Agreement.
On June 21, 2024, we terminated the Advisory Agreement, which was a condition to Mr. Lichtis appointment to the Board and as non-executive Chairman of the Board on the same date.

Stakeholder Impact

Shareholders: Potential dilution from future equity financing, uncertainty regarding long-term profitability.
Employees: Potential for job elimination/restructuring, as evidenced by the termination of the Chief Marketing Officer and Chief Commercial Officer.
Customers: Shift in focus from skincare to biotechnology may impact product availability and customer relationships.
Suppliers: Divestiture of skincare business may affect supplier agreements.
Creditors: Uncertainty regarding the company's ability to continue as a going concern may impact creditworthiness.

Next Steps

Grow revenue by achieving successful returns on capital through PMGC Capital LLC, our multi-strategy investment vehicle, by acquiring and managing undervalued assets, public and private investments, and structured financing opportunities.
Establish new wholly owned subsidiaries to develop and commercialize newly acquired or licensed biotechnology assets across various unrelated pharmaceutical indications.
Utilize clinical validation studies to strengthen the commercial potential and scientific credibility of our portfolio companies technologies.
Advance clinical development to progress NorthStrive Biosciences, Inc.'s clinical assets toward Investigational New Drug (IND) applications.
Pursue additional acquisitions of operating companies and biotechnology assets to expand and diversify our portfolio.
Evaluate potential spin-offs of wholly owned subsidiaries, creating new publicly traded companies to unlock shareholder value.

Key Dates

Date	Description
June 9, 2020	PMGC Holdings Inc. (formerly Elevai Labs Inc.) was incorporated in Delaware.
January 15, 2024	The Company entered into a license agreement with a Biotechnology company to use their proprietary technology and process to assist in formulating stem cells (License #1).
April 30, 2024	The Company entered into an exclusive license agreement with a pharmaceutical company granting the Company rights to develop, manufacture, and commercialize licensed products (License #2).
June 21, 2024	Graydon Bensler appointed as Chief Executive Officer and Chief Financial Officer of the Company.
November 27, 2024	The Company completed a reverse stock split on a ratio of two hundred old common shares for every one new post reverse split common share.
December 31, 2024	The Company entered into an asset purchase agreement to sell its skincare business.
January 16, 2025	The Company closed the sale of the skincare business.
March 10, 2025	The Company completed a second reverse stock split on a ratio of 7 common shares for every one new post second reverse split common share.
March 26, 2025	The shareholders approved the issuance of Series B Preferred Stock to GB Capital Ltd. and Northstrive Companies Inc.

Keywords

biotechnology, EL-22, PMGC Holdings, Northstrive Biosciences, weight loss, muscle preservation, GLP-1, clinical trials, FDA, acquisition

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.